Popat S, Matakidou A, Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004, 22 (3): 529-536.
Article
CAS
PubMed
Google Scholar
Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Lai R, Voloch A, Dumontet C: Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther. 2005, 4 (12): 2001-2007. 10.1158/1535-7163.MCT-05-0244.
Article
CAS
PubMed
Google Scholar
Longley DB, Johnston PG: Molecular mechanisms of drug resistance. J Pathol. 2005, 205 (2): 275-292. 10.1002/path.1706.
Article
CAS
PubMed
Google Scholar
Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008, 9 (10): 962-972. 10.1016/S1470-2045(08)70206-7.
Article
CAS
PubMed
Google Scholar
Leal JF, Garcia-Hernandez V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, Gago F, Guillen-Navarro MJ, Aviles P, Cuevas C, García-Fernández LF, Galmarini CM: Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines. Biochem Pharmacol. 2009, 78 (2): 162-170. 10.1016/j.bcp.2009.04.003.
Article
CAS
PubMed
Google Scholar
Colado E, Paino T, Maiso P, Ocio EM, Chen X, Alvarez-Fernandez S, Gutierrez NC, Martin-Sanchez J, Flores-Montero J, San Segundo L, Garayoa M, Fernández-Lázaro D, Vidriales MB, Galmarini CM, Avilés P, Cuevas C, Pandiella A, San-Miguel JF: Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica. 2011, 96 (5): 687-695. 10.3324/haematol.2010.036400.
Article
CAS
PubMed
PubMed Central
Google Scholar
Guirouilh-Barbat J, Antony S, Pommier Y: Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition. Mol Cancer Ther. 2009, 8 (7): 2007-2014. 10.1158/1535-7163.MCT-09-0336.
Article
CAS
PubMed
Google Scholar
Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW: DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry. 1996, 35 (41): 13303-13309. 10.1021/bi960306b.
Article
CAS
PubMed
Google Scholar
Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S: Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 2006, 66 (16): 8155-8162. 10.1158/0008-5472.CAN-06-0179.
Article
CAS
PubMed
Google Scholar
Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001, 7 (8): 961-966. 10.1038/91008.
Article
CAS
PubMed
Google Scholar
Erba E, Cavallaro E, Damia G, Mantovani R, Di Silvio A, Di Francesco AM, Riccardi R, Cuevas C, Faircloth GT, D’Incalci M: The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring. Oncol Res. 2004, 14 (11–12): 579-587.
CAS
PubMed
Google Scholar
Duan Z, Choy E, Jimeno JM, Cuevas Cdel M, Mankin HJ, Hornicek FJ: Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. Cancer Chemother Pharmacol. 2009, 63 (6): 1121-1129. 10.1007/s00280-008-0843-2.
Article
CAS
PubMed
Google Scholar
Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernandez S, San-Segundo L, Vilanova D, Lopez-Corral L, Montero JC, Hernandez-Iglesias T, de Alava E, Galmarini C, Avilés P, Cuevas C, San-Miguel JF, Pandiella A: Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood. 2009, 113 (16): 3781-3791. 10.1182/blood-2008-09-177774.
Article
CAS
PubMed
Google Scholar
Moneo V, Serelde BG, Fominaya J, Leal JF, Blanco-Aparicio C, Romero L, Sanchez-Beato M, Cigudosa JC, Tercero JC, Piris MA, Jimeno J, Carnero A: Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem. 2007, 100 (2): 339-348. 10.1002/jcb.21073.
Article
CAS
PubMed
Google Scholar
Chou AJ, Geller DS, Gorlick R: Therapy for osteosarcoma: where do we go from here?. Paediatr Drugs. 2008, 10 (5): 315-327. 10.2165/00148581-200810050-00005.
Article
PubMed
Google Scholar
Leal JF, Fominaya J, Cascon A, Guijarro MV, Blanco-Aparicio C, Lleonart M, Castro ME, Ramon YCS, Robledo M, Beach DH, Carnero A: Cellular senescence bypass screen identifies new putative tumor suppressor genes. Oncogene. 2008, 27 (14): 1961-1970. 10.1038/sj.onc.1210846.
Article
CAS
PubMed
Google Scholar
Moneo V, Serelde BG, Leal JF, Blanco-Aparicio C, Diaz-Uriarte R, Aracil M, Tercero JC, Jimeno J, Carnero A: Levels of p27(kip1) determine Aplidin sensitivity. Mol Cancer Ther. 2007, 6 (4): 1310-1316. 10.1158/1535-7163.MCT-06-0729.
Article
CAS
PubMed
Google Scholar
Master SR: Getting the details right: gene signatures for cancer therapy. Clin Chem. 2010, 56 (9): 1378-1380. 10.1373/clinchem.2010.147686.
Article
CAS
PubMed
Google Scholar
Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Marks JR, Dressman HK, West M, Nevins JR: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006, 439 (7074): 353-357. 10.1038/nature04296.
Article
CAS
PubMed
Google Scholar
Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008, 8 (3): 187-198. 10.2174/156800908784293659.
Article
CAS
PubMed
Google Scholar
Blanco-Aparicio C, Pequeno B, Moneo V, Romero L, Leal JF, Velasco J, Fominaya J, Carnero A: Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria. Anticancer Drugs. 2005, 16 (9): 977-987. 10.1097/01.cad.0000180117.93535.cf.
Article
CAS
PubMed
Google Scholar
Gardai SJ, Hildeman DA, Frankel SK, Whitlock BB, Frasch SC, Borregaard N, Marrack P, Bratton DL, Henson PM: Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem. 2004, 279 (20): 21085-21095. 10.1074/jbc.M400063200.
Article
CAS
PubMed
Google Scholar
Yamaguchi H, Wang HG: The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene. 2001, 20 (53): 7779-7786. 10.1038/sj.onc.1204984.
Article
CAS
PubMed
Google Scholar
Link W, Rosado A, Fominaya J, Thomas JE, Carnero A: Membrane localization of all class I PI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt. J Cell Biochem. 2005, 95 (5): 979-989. 10.1002/jcb.20479.
Article
CAS
PubMed
Google Scholar
Zanella F, Link W, Carnero A: Understanding FOXO, new views on old transcription factors. Curr Cancer Drug Targets. 2010, 10 (2): 135-146. 10.2174/156800910791054158.
Article
CAS
PubMed
Google Scholar
Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M: Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene. 2002, 21 (8): 1299-1303. 10.1038/sj.onc.1205181.
Article
CAS
PubMed
Google Scholar
Cox AD, Der CJ: The dark side of Ras: regulation of apoptosis. Oncogene. 2003, 22 (56): 8999-9006. 10.1038/sj.onc.1207111.
Article
CAS
PubMed
Google Scholar
Mayo MW, Norris JL, Baldwin AS: Ras regulation of NF-kappa B and apoptosis. Methods Enzymol. 2001, 333: 73-87.
Article
CAS
PubMed
Google Scholar
Jones HE, Gee JM, Hutcheson IR, Knowlden JM, Barrow D, Nicholson RI: Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer. 2006, 13 (Suppl 1): S45-S51.
Article
CAS
PubMed
Google Scholar
Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I: Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets. 2009, 13 (3): 339-362. 10.1517/14712590902735795.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hrustanovic G, Lee BJ, Bivona TG: Mechanisms of resistance to EGFR targeted therapies. Cancer Biol Ther. 2013, 14 (4): 304-314. 10.4161/cbt.23627.
Article
CAS
PubMed
PubMed Central
Google Scholar
Beech DJ, Perer E, Helms J, Gratzer A, Deng N: Insulin-like growth factor-I receptor activation blocks doxorubicin cytotoxicity in sarcoma cells. Oncol Rep. 2003, 10 (1): 181-184.
CAS
PubMed
Google Scholar
Braun AH, Stark K, Dirsch O, Hilger RA, Seeber S, Vanhoefer U: The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan. Anticancer Drugs. 2005, 16 (10): 1099-1108. 10.1097/00001813-200511000-00009.
Article
CAS
PubMed
Google Scholar
Michaelis M, Bliss J, Arnold SC, Hinsch N, Rothweiler F, Deubzer HE, Witt O, Langer K, Doerr HW, Wels WS, Cinatl J: Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins. Clin Cancer Res. 2008, 14 (20): 6531-6537. 10.1158/1078-0432.CCR-08-0821.
Article
CAS
PubMed
Google Scholar
Jaboin J, Kim CJ, Kaplan DR, Thiele CJ: Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3′-kinase pathway. Cancer Res. 2002, 62 (22): 6756-6763.
CAS
PubMed
Google Scholar
Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, Thomas H: Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Biochem Pharmacol. 2006, 72 (8): 941-948. 10.1016/j.bcp.2006.07.022.
Article
CAS
PubMed
Google Scholar
Hsu CH, Gao M, Chen CL, Yeh PY, Cheng AL: Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. Oncology. 2005, 68 (4–6): 538-547.
Article
CAS
PubMed
Google Scholar
Mattingly RR, Milstein ML, Mirkin BL: Down-regulation of growth factor-stimulated MAP kinase signaling in cytotoxic drug-resistant human neuroblastoma cells. Cell Signal. 2001, 13 (7): 499-505. 10.1016/S0898-6568(01)00173-5.
Article
CAS
PubMed
Google Scholar
Takeuchi A, Eto M, Shiota M, Tatsugami K, Yokomizo A, Kuroiwa K, Itsumi M, Naito S: Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation. Int J Oncol. 2012, 40 (5): 1691-1696.
CAS
PubMed
Google Scholar
Estevez-Garcia P, Castano A, Martin AC, Lopez-Rios F, Iglesias J, Munoz-Galvan S, Lopez-Calderero I, Molina-Pinelo S, Pastor MD, Carnero A, Paz-Ares L, Garcia-Carbonero R: PDGFRalpha/beta and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome. BMC Cancer. 2012, 12: 514-10.1186/1471-2407-12-514.
Article
CAS
PubMed
PubMed Central
Google Scholar
van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009, 35 (8): 692-706. 10.1016/j.ctrv.2009.08.004.
Article
CAS
PubMed
Google Scholar